Shanghai XBH Biotechnology Co., Ltd.

CAMBRIDGE, Mass., Aug. 21, 2024 /PRNewswire/ -- GV20 Therapeutics, a clinical-stage AI and genomics-based next generation biotherapeutics company announced today that Dr. Kristopher Wentzel from The Angeles Clinic and Research Institute will present the clinical data on GV20-0251 monotherapy dose escalation at the ESMO Congress 2024, taking place in Barcelona on Sept 13-17, 2024. GV20-251 is the first clinical stage, AI-designed antibody therapeutic against an AI-predicted target in the clinic. The monotherapy dose escalation study started on Mar 27, 2023, and has enrolled across six dose cohorts and two schedules. GV20-0251 has shown favorable safety profile and promising monotherapy clinical efficacy. Details of the oral presentation are below: Title: "A phase 1/2, open-label study of the novel checkpoint IGSF8 inhibitor GV20-0251 in patients with advanced solid tumors" Session Type: Mini oral session Session Title: Investigational Immunotherapy Session Date/Time: Monday Sep 16, 2024, 10:15-11:45AM Session Room: Granada Auditorium - Hall 6 Presentation Number: 1000MO ABOUT GV20 THERAPEUTICS GV20 Therapeutics is developing a differentiated pipeline of next generation biotherapeutics integrating AI, genomics, & disease biology. Our lead program, GV20-0251, a first-in-class, fully human, Fc-attenuated IgG1 monoclonal antibody targeting a novel immune checkpoint IGSF8 to activate innate and adaptive immunity, is in a multi-center Phase 1/2 clinical trial in patients with advanced solid tumors (NCT05669430). Our discovery pipeline includes best-in-class and first-in-class ADCs and degraders. GV20 is headquartered in Cambridge, MA. To learn more about GV20, please visit and follow the company on LinkedIn. Business Contact Ying Gong, Ph.D., CBO [email protected] SOURCE GV20 Therapeutics

CAMBRIDGE, Mass., April 18, 2024 /PRNewswire/ -- GV20 Therapeutics, a clinical stage biotechnology company integrating AI, genomics, and disease biology to create next-generation antibody therapeutics, today announced that it has entered into a clinical collaboration and supply agreement with Merck (known as MSD outside the US and Canada). Under the terms of the agreement, GV20 will evaluate its lead investigational program GV20-0251, a first-in-class antibody targeting the novel immune checkpoint IGSF8, in combination with Merck's anti-PD-1 therapy, KEYTRUDA®(pembrolizumab), in patients with advanced solid tumors in an ongoing Phase I study (NCT05669430). "We are excited to advance the development of GV20-0251 and explore its potential in combination with KEYTRUDA," said Dr. Shirley Liu, Co-Founder and CEO of GV20 Therapeutics. "IGSF8 is a novel immune checkpoint target that inhibits the function of natural killer cells and dendritic cells. By releasing this inhibition, the antagonistic antibody GV20-0251 has the potential to become another pillar in cancer immunotherapy and bring significant benefits to cancer patients." GV20 is currently enrolling an open-label, multi-center, dose-escalation and dose-expansion Phase I clinical trial testing GV20-0251 in patients with advanced solid tumors who are not eligible for standard of care therapies (NCT05669430). The study is designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of GV20-0251 as a single agent and in combination with KEYTRUDA®(pembrolizumab). GV20 has generated preclinical data demonstrating that antibody blockade of IGSF8 results in compelling anti-tumor activity as monotherapy as well as in combination with anti-PD-1 across multiple tumor models. Recently, at the American Association for Cancer Research (AACR) Annual Meeting 2024, GV20 delivered an oral presentation titled "IGSF8 is a novel innate immune checkpoint and cancer immunotherapy target" during the immunology mini-symposium session. KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA. ABOUT GV20 THERAPEUTICS At GV20 Therapeutics, our mission is to develop a differentiated pipeline of innovative antibody therapeutics to transform the treatment of cancer. We leverage our in-house STEAD platform (Simultaneous Target Evaluation and Antibody Discovery), which integrates AI, genomics, and disease biology to identify novel drug targets and create next-generation therapies against these targets. Our lead program, GV20-0251, a first-in-class, fully human, Fc-attenuated IgG1 monoclonal antibody targeting IGSF8, is in a multi-center Phase I clinical trial in patients with advanced solid tumors (NCT05669430). GV20 is headquartered in Cambridge, MA. To learn more about GV20, please visit and follow the company on LinkedIn. Business Contact Ying Gong, Ph.D., CBO [email protected] SOURCE GV20 Therapeutics

-GV20-0251 is the first ever AI-designed antibody against an AI-predicated target to advance into the clinic- CAMBRIDGE, Mass., April 8, 2024 /PRNewswire/ -- GV20 Therapeutics a clinical-stage biotechnology company integrating AI, genomics, and disease biology to create next-generation antibody therapeutics for cancer, today presented preclinical data on it GV20-0251 program during an oral presentation at the American Association of Cancer Research (AACR) Annual Meeting 2024 in San Diego, CA. "I am honored to showcase our novel technology platform and present the previously unknown immune function of IGSF8 at AACR 2024. GV20-0251 is the first ever AI-designed antibody against an AI-predicated target to advance into the clinic and can potentially bring significant benefits to patients with solid tumors," said Shirley Liu, CEO of GV20 Therapeutics. "We have made great progress on GV20-0251 Phase I dose escalation and look forward to advancing into monotherapy cohort expansion and combination studies later this year." The oral presentation at AACR included an overview on the company's novel discovery and development process of its lead antibody, GV20-0251, which antagonizes a novel cancer immunotherapy target, IGSF8. Many cancer patients' immune systems make anti-PD1/anti-PDL1 antibodies, however the patients do not make enough and have the wrong IgA Fc to completely kill the tumors. GV20 uses tens of thousands of tumors as experimental systems and leverages artificial intelligence (AI) to mine big data from large tumor profiles to predict the antibodies in patient tumors that can be developed into cancer drugs. Through this modeling, GV20 discovered that IGSF8 is a novel innate immune checkpoint highly expressed on malignant cells with antigen presentation defects. Anti-IGSF8 enhances NK cell killing, antigen presentation, and turns immune-cold tumors hot. In addition, anti-IGSF8 alone or in combination with anti-PD1 inhibits tumor growth in multiple models, including some known to resist anti-PD1 therapy. GV20's in-house STEAD platform (Simultaneous Target Evaluation and Antibody Discovery), which integrates AI, genomics, and disease biology, can not only identify novel drug targets, but also create next-generation therapies against these targets, like GV20-0251. The ongoing Phase I study in solid tumors (NCT05669430) is advancing and GV20-0251 is demonstrating promising early clinical activities. Details of the oral presentation at AACR are below: Title: "IGSF8 is a novel innate immune checkpoint and cancer immunotherapy target" Session Type: Minisymposium Session Category: Immunology Session Title: Immune Targets and Therapies Session Date/Time: Monday Apr 8, 2024, 2:30 PM - 4:30 PM Abstract Presentation Number: 3914 ABOUT GV20 THERAPEUTICS At GV20 Therapeutics, our mission is to develop a differentiated pipeline of innovative antibody therapeutics to transform cancer treatment. We leverage our in-house STEAD platform (Simultaneous Target Evaluation and Antibody Discovery), which integrates AI, genomics, and disease biology to identify novel drug targets and create next-generation therapies against these targets. Our lead program, GV20-0251, a first-in-class, fully human, Fc-attenuated IgG1 monoclonal antibody targeting a novel innate immune checkpoint IGSF8, is in a multi-center Phase I clinical trial in patients with advanced solid tumors (NCT05669430). GV20 is headquartered in Cambridge, MA. To learn more about GV20, please visit and follow the company on LinkedIn. Business Contact Ying Gong, Ph.D., CBO BD@gv20tx.com Investor and Media Contact Amy Conrad Juniper Point amy@juniper-point.com